Who
Jeetinder Singh Mahal
CEO and President
Company insider
Files Form 4 as: CEO and President, Jasper Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $99K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 21 Mar 2022
- Last trade
- 6 Feb 2026
- Last filed
- 10 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Feb 2026filed 10 Feb 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Dec 2024filed 12 Dec 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —900 at $0.00 | filing |
| 12 Dec 2024filed 12 Dec 2024 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,390900 at $7.10 | filing |
| 12 Dec 2024filed 12 Dec 2024 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K900 at $22.11 | filing |
| 12 Sep 2024filed 12 Sep 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —900 at $0.00 | filing |
| 12 Sep 2024filed 12 Sep 2024 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,390900 at $7.10 | filing |
| 12 Sep 2024filed 12 Sep 2024 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K900 at $21.23 | filing |
| 12 Jun 2024filed 12 Jun 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —900 at $0.00 | filing |
| 12 Jun 2024filed 12 Jun 2024 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,390900 at $7.10 | filing |
| 12 Jun 2024filed 12 Jun 2024 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K900 at $24.16 | filing |
| 12 Mar 2024filed 12 Mar 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —900 at $0.00 | filing |
| 12 Mar 2024filed 12 Mar 2024 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,390900 at $7.10 | filing |
| 12 Mar 2024filed 12 Mar 2024 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Sold | $24K900 at $26.44 | filing |
| 15 Feb 2024filed 20 Feb 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 12 Oct 2023filed 13 Oct 2023 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code F | $32K37,126 at $0.85 | filing |
News
No headline names them, or the companies they trade most, lately.